Tetra Radar · FDA Approvals · Decision date
zanzalintinib: FDA decision date
Exelixis, Inc. (EXEL) · 3 December 2026
In February 2026, we announced that the FDA had accepted our NDA and assigned a standard review, with a Prescription Drug User Fee Act (PDUFA) target action date of December 3, 2026.
Source: 10-Q of 29 October 2026
The decision is pending.
A PDUFA date is the date by which the FDA has said it will decide on an application. Dates can move, and a decision is not an approval. Tetra Radar observes public information for research purposes. It does not provide investment advice.